Quadrant Biosciences
Syracuse, US · Delaware corporation
Founders & leadership
RU
Richard UhligFounder
EA
Erica AshExecutive
JC
James CrokeExecutive
RB
Richard BongoinExecutive
NG
Nicholas GianaddaExecutive
BG
Bryan GreeneinExecutive
Board
AR
Andrew RockBoard director
PC
Peter CohenBoard director
IF
Ira FedderBoard director
MA
Mary Ann TyszkoBoard director
Funding
SEC filings, press & company announcements$11.9M disclosed across 5 of 7 rounds · 2015–2025
- Undisclosed amountSeries AFeb 2025Source ↗
▶$25.4MofferedNov 2023 · BiotechnologyRule 506(c)
▶$25.4MofferedNov 2023 · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Erica AshExecutive Officer
- James CrokeExecutive Officer, Director
- Andrew RockDirector
- Peter CohenDirector
- Richard BongoExecutive Officer, Director
- Nicholas GianaddaExecutive Officer
- Ira FedderDirector
- Mary Ann TyszkoDirector
- Bryan GreeneExecutive Officer
- Richard UhligExecutive Officer, Director
- Offering amount
- $25.4M
- Minimum investment
- $50K
- Proceeds to insiders
- $1.1M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$3.5MraisedAug 2023 · 6 investors · BiotechnologyRule 506(b)
▶$3.5MraisedAug 2023 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bryan GreeneExecutive Officer
- Richard BongoExecutive Officer, Director
- Mary Ann TyszkoDirector
- Erica AshExecutive Officer
- Richard UhligExecutive Officer, Director
- Ira FedderDirector
- Peter CohenDirector
- Andrew RockDirector
- James CrokeExecutive Officer, Director
- Nicholas GianaddaExecutive Officer
- Offering amount
- $35M
- Amount sold
- $3.5M
- Minimum investment
- $50K
- Proceeds to insiders
- $1.1M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedJan 2020 · 20 investors · BiotechnologyRule 506(b)
▶$2.3MraisedJan 2020 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wade WestExecutive Officer, Director
- Richard BongoExecutive Officer, Director
- Chris HoracekExecutive Officer
- Scott GiambalvoExecutive Officer
- Alexander RajanExecutive Officer
- Kayla WagnerExecutive Officer
- Andrew BrindleExecutive Officer
- Patrick BaileyExecutive Officer
- Randy CarpenterExecutive Officer
- Benjamin PerryExecutive Officer
- Bryan GreeneExecutive Officer
- Mary Ann TyszkoDirector
- Ira FedderDirector
- Andrew RockDirector
- Peter CohenDirector
- Richard UhligExecutive Officer, Director
- James CrokeExecutive Officer, Director
- Jeremy WilliamsExecutive Officer
- Offering amount
- $5M
- Amount sold
- $2.3M
- Minimum investment
- $5K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$450KraisedJun 2019 · 6 investors · BiotechnologyRule 506(b)
▶$450KraisedJun 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David MacLeanExecutive Officer
- Kayla WagnerExecutive Officer
- Alexander Rajan, PhDExecutive Officer
- Chris HoracekExecutive Officer
- Scott GiambalvoExecutive Officer
- Andrew BrindleExecutive Officer
- Patrick BaileyExecutive Officer
- Randy CarpenterExecutive Officer
- Benjamin PerryExecutive Officer
- Wade WestExecutive Officer, Director
- Richard BongoExecutive Officer, Director
- James CrokeExecutive Officer, Director
- Richard UhligExecutive Officer, Director
- Bryan GreeneExecutive Officer
- Jeremy WilliamsExecutive Officer
- Mary Ann TyszkoDirector
- Ira FedderDirector
- Andrew RockDirector
- Peter CohenDirector
- Offering amount
- $5M
- Amount sold
- $450K
- Minimum investment
- $5K
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2.1MraisedDec 2016 · 30 investors · BiotechnologyRule 506(b)
▶$2.1MraisedDec 2016 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard BongoDirector
- Mary K. TyszkoDirector
- Richard UhligExecutive Officer, Director
- Cindy Dowd GreeneDirector
- Andrew RockDirector
- Gary Wade West, Jr.Director
- Ira FedderDirector
- Offering amount
- $2.5M
- Amount sold
- $2.1M
- Minimum investment
- $10K
- Proceeds to insiders
- $150K
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3.6MraisedApr 2016 · 36 investors · BiotechnologyRule 506(b)
▶$3.6MraisedApr 2016 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard UhligExecutive Officer, Director
- Mary K. TyszkoDirector
- Andrew RockDirector
- Ira FedderDirector
- David MacLeanDirector
- Cindy Dowd GreeneDirector
- Richard BongoDirector
- Offering amount
- $5M
- Amount sold
- $3.6M
- Minimum investment
- $10K
- Proceeds to insiders
- $150K
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $311.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2018 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who founded Quadrant Biosciences?
- Quadrant Biosciences was founded by Richard Uhlig.
- How much funding has Quadrant Biosciences raised?
- Quadrant Biosciences has disclosed $11.9M raised across 5 of its 7 known rounds.
- Where is Quadrant Biosciences headquartered?
- Quadrant Biosciences is headquartered in Syracuse, US.